BackNatera Overview
Natera Inc

Natera Target Price

See Natera's analyst price targets ($300) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$326.26

Average Target Price

$303.097.1% downside

23 analysts in the last 4 months

High: $375 | Low: $220

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-12Stephens$3507.3% upsideOpen
2026-08-12Guggenheim$36010.3% upsideOpen
2026-08-10Morgan Stanley$3558.8% upsideOpen
2026-08-07RBC Capital$3507.3% upsideOpen
2026-08-07Robert W. BairdCatherine Ramsey Schulte$3486.7% upsideOpen
2026-08-07Canaccord GenuityKyle Mikson$37514.9% upsideOpen
2026-08-07Wells Fargo$28413% downsideOpen
2026-08-07BTIG$3201.9% downsideOpen
2026-08-07Leerink Partners$3301.1% upsideOpen
2026-08-07Barclays$3404.2% upsideOpen
2026-07-14Canaccord Genuity$3301.1% upsideOpen
2026-07-09Morgan Stanley$3105% downsideOpen
2026-07-06Evercore ISI$3008% downsideOpen
2026-06-29GuggenheimSubbu Nambi$29011.1% downsideOpen
2026-06-24BTIG$27515.7% downsideOpen
2026-06-24UBS$26020.3% downsideOpen
2026-06-23BTIG$27017.2% downsideOpen
2026-06-11RBC CapitalDan Leonard$27515.7% downsideOpen
2026-06-05Goldman SachsEvie Koslosky$24524.9% downsideOpen
2026-05-12Piper Sandler$24923.7% downsideOpen
2026-05-08Robert W. Baird$26518.8% downsideOpen
2026-05-08Evercore ISI$27017.2% downsideOpen
2026-05-08Wells FargoBrandon Couillard$22032.6% downsideOpen
2026-01-05Guggenheim$27017.2% downsideOpen
2025-12-22Canaccord Genuity$28512.6% downsideOpen
2025-12-15Wells Fargo$20537.2% downsideOpen
2025-12-15Barclays$27017.2% downsideOpen
2025-12-01Morgan Stanley$26518.8% downsideOpen
2025-11-18UBS$28014.2% downsideOpen
2025-10-27BNP ParibasNavann Ty$17247.3% downsideOpen
2025-09-22Wells FargoBrandon Couillard$17546.4% downsideOpen
2025-09-02RBC CapitalConor McNamara$26817.9% downsideOpen
2025-08-10Morgan StanleyPatrick Wood$19540.2% downsideOpen
2025-02-28Canaccord Genuity$19540.2% downsideOpen
2024-11-13JefferiesTycho Peterson$18244.2% downsideOpen
2024-11-13Robert W. BairdCatherine Ramsey Schulte$16051% downsideOpen
2024-10-29Canaccord GenuityKyle Mikson$15054% downsideOpen
2024-09-13Piper SandlerDave Westenberg$15054% downsideOpen
2024-08-27Canaccord GenuityKyle Mikson$14555.6% downsideOpen
2024-08-13Morgan StanleyTejas Savant$13259.5% downsideOpen
2024-08-09Robert W. BairdCatherine Ramsey Schulte$12063.2% downsideOpen
2024-06-25Wolfe ResearchDoug Schenkel$13558.6% downsideOpen
2024-06-03JefferiesTycho Peterson$14256.5% downsideOpen
2024-05-14Piper SandlerDavid Westenberg$12063.2% downsideOpen
2024-05-13BTIGMark Massaro$12561.7% downsideOpen
2024-05-10Robert W. BairdCatherine Ramsey Schulte$11764.1% downsideOpen
2024-04-05BernsteinEve Burstein$12063.2% downsideOpen
2022-11-14Credit Suisse$5583.1% downsideOpen
2022-08-17Piper SandlerDavid Westenberg$7078.5% downsideOpen
2022-08-05J.P. Morgan$10069.3% downsideOpen

Natera (NTRA) FAQ

Natera posts a target price of $300. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $300 for NTRA means covering analysts, on average, see the stock 7.1% downside of $326.26 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for NTRA's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Natera's other metric pages and overview cover the third.

Judging Natera against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $300 here, then scan peer and history charts to see if the gap is persistent.